Verrica Pharmaceuticals
VRCA
50 hedge funds and large institutions have $29.8M invested in Verrica Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 10 closing their positions.
117% more call options, than puts
Call options by funds: $176K | Put options by funds: $81K
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
2% more funds holding
Funds holding: 49 → 50 (+1)
0.14% more ownership
Funds ownership: 2.49% → 2.63% (+0.14%)
1% less capital invested
Capital invested by funds: $29.9M → $29.8M (-$158K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$351K |
| 2 |
CI
Conning Inc
Hartford,
Connecticut
|
+$344K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$133K |
| 4 |
E
Ergoteles
New York
|
+$94.9K |
| 5 |
Kovitz Investment Group Partners
Chicago,
Illinois
|
+$80.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.42M |
| 2 |
BlackRock
New York
|
-$519K |
| 3 |
FI
Fosun International
Hong Kong,
China
|
-$409K |
| 4 |
Renaissance Technologies
New York
|
-$197K |
| 5 |
Morgan Stanley
New York
|
-$77.7K |
VRCA Hedge Fund Activity: Q4 2022 in Review
50 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q4 2022, worth a combined $29.8M — down 0.53% from $29.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new VRCA positions and 10 closed out — a net gain of 1 holder — while 16 added to existing stakes and 12 trimmed.
The largest buyer was Millennium Management, adding an estimated $351K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.42M sold.
- 50 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q4 2022, up from 49 in Q3 2022.
- Funds reported $29.8M of Verrica Pharmaceuticals stock for Q4 2022, down 0.53% quarter-over-quarter.
- 11 funds opened new Verrica Pharmaceuticals positions in Q4 2022 and 10 closed out, a net change of +1 holder.
- The largest Verrica Pharmaceuticals buyer in Q4 2022 was Millennium Management, an estimated $351K added.
- The largest Verrica Pharmaceuticals seller in Q4 2022 was Point72 Asset Management, an estimated $1.42M sold.
Based on aggregated 13F filings for Q4 2022.